The risk of developing prostate cancer among older men who receive testosterone replacement therapy for low testosterone is no greater than it is for similarly aged men not treated with testosterone, according to a study presented at The Endocrine Society’s annual meeting in San Francisco.

Chances of surviving prostate cancer in men whose tumors recur after prostatectomy are threefold higher for those who undergo radiotherapy within 2 years after recurrence, according to new research findings from the Johns Hopkins Medical Institutions in Baltimore. In men whose new tumors grew fastest, prolonged survival chances were greatest, researchers reported last week in JAMA (2008; 299:2760-9).

A panel of seven biomarkers can predict with 86% accuracy which prostate cancer patients will experience recurrence and progression of prostate cancer, researchers from the University of Texas Southwestern Medical Center in Dallas reported in Clinical Cancer Research (2008; 14:3785-91).

The form of tomato product one eats could be the key to unlocking its prostate cancer-fighting potential, researchers from the University of Missouri, Columbia, recently reported in Cancer Research (2008; 68:4384-91).

Modern 3-D computed tomography is effective for locating the prostatic apex for radiation therapy treatment planning in prostate cancer patients because it eliminates the need for an invasive procedure and related side effects, according to a study in the International Journal of Radiation Oncology Biology Physics (2008; 71:51-7).

An extensive re-analysis of the drug finasteride (Proscar) shows that it reduced the risk of developing prostate cancer by about 30% compared with the initial finding of a 25% reduction in risk.

Estrogen-linked signaling helps drive a discrete and aggressive form of prostate cancer caused by a chromosomal translocation, which, in turn, results in the fusion of two genes, researchers report.

Results of a study based on data from approximately 43,400 men show risks of developing melanoma and prostate cancer are increased among those with a diagnosis of male factor infertility, reported researchers from the University of California, San Francisco.

FDA has cleared the use of the implantable Beacon electromagnetic transponders with Calypso Medical's Calypso System in external beam radiation therapy for post-prostatectomy patients. Previously, the system (known as "GPS for the Body") was cleared solely for use in patients with an intact prostate.